191 patents
Page 8 of 10
Utility
Methods of Using Tumor Infiltrating Lymphocytes In Double-refractory Melanoma
20 May 21
Methods of treating melanomas refractory to other therapies using tumor infiltrating lymphocytes are disclosed.
Maria Fardis
Filed: 5 Jun 18
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
18 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
18 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Expansion of Tumor Infiltrating Lymphocytes (Tils) with Adenosine A2A Receptor Antagonists and Therapeutic Combinations of Tils and Adenosine A2A Receptor Antagonists
13 May 21
Methods of expanding tumor infiltrating lymphocytes (TILs) in the presence of an adenosine A2A receptor (A2aR) antagonist, such as vipadenant, CPI-444 (ciforadenant), SCH58261, SYN115, ZM241385, SCH420814, a xanthine superfamily A2aR antagonist, or related adenosine receptor 2A antagonist, and uses of expanded TILs in the treatment of diseases such as cancer are disclosed herein.
Maria Fardis
Filed: 12 Feb 19
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
13 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Closed Process for Expansion and Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 26 Apr 19
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 12 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 12 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 12 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TLs and producing therapeutic populations of TTLs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TLs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 12 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
6 May 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 18 Dec 20
Utility
Remnant Tumor Infiltrating Lymphocytes and Methods of Preparing and Using the Same
29 Apr 21
In some embodiments, methods of delivering a therapeutically effective amount of an expanded number of tumor infiltrating lymphocytes obtained from tumor remnants to a patient in need thereof, for the treatment of a cancer, are disclosed.
Michelle R. Simpson-Abelson, Christopher Mosychuk, Michael T. Lotze
Filed: 5 Jan 21
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Apr 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 2 Dec 20
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Apr 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 2 Dec 20
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
23 Mar 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 14 Apr 20
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
23 Mar 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 14 Apr 20
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
18 Mar 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 29 Jun 18
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
16 Mar 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 14 Apr 20
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
16 Mar 21
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 14 Apr 20